PDB4 AN EVALUATION OF THE COST OF DIABETES-RELATED MEDICATION FOLLOWING INITIATION OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN THE UK FROM OBSERVATIONAL, REAL-LIFE DATA FROM GENERAL PRACTICE

Purpose – The purpose of this paper is to illustrate an optimisation method, and resulting insights, for minimising total logistics-related carbon emissions for end-to-end supply chains. Design/methodology/approach – The research is based on two real-life UK industrial cases. For the first case, several alternative realistic routes towards the UK are analysed and the optimal route minimising total carbon emissions is identified and tested in real conditions. For the second case, emissions towards several destinations are calculated and two alternative routes to southern Europe are compared, using several transport modes (road, Ro-Ro, rail and maritime). An adapted Value Stream Mapping (VSM) approach is used to map carbon footprint and calculate emissions; in addition Automatic Identification Systems (AIS) data provided information for vessel specification allowing the use of more accurate emission factors for each shipping leg. Findings – The analysis of the first case demonstrates that end-to-end logistics-related carbon emissions can be reduced by 16-21 per cent through direct delivery to the UK as opposed to transhipment via a Continental European port. The analysis of the second case shows that deliveries to southern Europe have the highest potential for reduction through deliveries by sea. Both cases show that for distant overseas destinations, the maritime leg represents the major contributor to CO2 emissions in the end-to-end supply chain. It is notable that one of the main apportionment approaches (that of Defra in the UK) generate higher carbon footprints for routes using Ro-Pax vessels, making those not optimal. The feasibility of the optimal route was demonstrated with real-life data. Originality/value – This research used real-life data from two UK companies and highlighted where carbon emissions are generated in the inbound and outbound transport chain, and how these can be reduced.

Download Full-text

PDB29 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN USING UK REAL LIFE DATA IN TYPE 1 DIABETES MELLITUS ANDTHE COMBINED EFFECT OF HBA1C AND HYPOGLYCAEMIA REDUCTION

Value in Health ◽

10.1016/s1098-3015(10)64977-7 ◽

2007 ◽

Vol 10 (6) ◽

pp. A262-A263 ◽

Cited By ~ 1

Author(s):

P McEwan ◽

N Mehin ◽

AP Tetlow ◽

P Sharplin

Keyword(s):

Diabetes Mellitus ◽

Type 1 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Real Life ◽

Relative Cost ◽

Nph Insulin ◽

Life Data ◽

Real Life Data

Download Full-text

Economic Evaluation of Different Screening Strategies for Severe Combined Immunodeficiency Based on Real-Life Data

International Journal of Neonatal Screening ◽

10.3390/ijns7030060 ◽

2021 ◽

Vol 7 (3) ◽

pp. 60

Author(s):

M. Elske van den Akker-van Marle ◽

Maartje Blom ◽

Mirjam van der Burg ◽

Robbert G. M. Bredius ◽

Catharina P. B. Van der Ploeg

Keyword(s):

Cost Effectiveness ◽

Severe Combined Immunodeficiency ◽

Real Life ◽

Final Diagnosis ◽

Screening Strategy ◽

Combined Immunodeficiency ◽

Life Data ◽

Real Life Data ◽

Screening Strategies ◽

The Cost

Although several countries have adopted severe combined immunodeficiency (SCID) into their newborn screening (NBS) program, other countries are still in the decision process of adding this disorder in their program and finding the appropriate screening strategy. This decision may be influenced by the cost(-effectiveness) of these screening strategies. In this study, the cost(-effectiveness) of different NBS strategies for SCID was estimated based on real-life data from a prospective implementation study in the Netherlands. The cost of testing per child for SCID was estimated at EUR 6.36. The cost of diagnostics after screen-positive results was assessed to vary between EUR 985 and 8561 per child dependent on final diagnosis. Cost-effectiveness ratios varied from EUR 41,300 per QALY for the screening strategy with T-cell receptor excision circle (TREC) ≤ 6 copies/punch to EUR 44,100 for the screening strategy with a cut-off value of TREC ≤ 10 copies/punch. The analysis based on real-life data resulted in higher costs, and consequently in less favorable cost-effectiveness estimates than analyses based on hypothetical data, indicating the need for verifying model assumptions with real-life data. The comparison of different screening strategies suggest that strategies with a lower number of referrals, e.g., by distinguishing between urgent and less urgent referrals, are favorable from an economic perspective.

Download Full-text